Biophytis S.A.
Clinical-stage biotech developing drugs for age-related neuromuscular and retinal diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow the degenerative processes associated with aging and improve functional outcomes for patients. The company's scientific approach targets and activates key biological resilience pathways to counteract the effects of stresses leading to age-related diseases. Its lead drug candidate, BIO101 (20-hydroxyecdysone), is an orally administered small molecule in late-stage clinical development for neuromuscular conditions, including sarcopenia (Phase 3) and muscle wasting associated with obesity (Phase 2). The company's pipeline also includes Macuneos (BIO201), a small molecule being developed for retinal diseases such as dry age-related macular degeneration (AMD) and Stargardt disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-04 07:00 |
Regulatory News Service
Biophytis announces its participation in the BIO International Convention from …
|
English | 155.1 KB | ||
| 2025-06-04 07:00 |
Regulatory News Service
Biophytis annonce sa participation à la BIO International Convention du 16 au 1…
|
French | 161.2 KB | ||
| 2025-05-30 22:00 |
Report Publication Announcement
Information on the Annual Financial Statements
|
English | 103.8 KB | ||
| 2025-05-30 22:00 |
Report Publication Announcement
Information sur les comptes annuels
|
French | 172.5 KB | ||
| 2025-05-15 07:00 |
Environmental & Social Information
Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 20…
|
English | 144.3 KB | ||
| 2025-05-15 07:00 |
Regulatory News Service
Biophytis met en lumière son approche innovante du traitement de l’obésité lors…
|
French | 129.9 KB | ||
| 2025-04-22 07:00 |
Regulatory News Service
Biophytis cible la restauration de la mobilité chez les patients obèses
|
French | 143.1 KB | ||
| 2025-04-22 07:00 |
Earnings Release
Biophytis targets mobility restoration in patients with obesity
|
English | 140.1 KB | ||
| 2025-04-09 07:00 |
Regulatory News Service
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
|
English | 175.0 KB | ||
| 2025-04-09 07:00 |
Regulatory News Service
Biophytis confirme le lancement de l’essai clinique de Phase 2 OBA dans l’obési…
|
French | 169.7 KB | ||
| 2025-03-28 22:00 |
Share Issue/Capital Change
Biophytis announces the settlement and delivery of its €2.6 million private pla…
|
English | 534.3 KB | ||
| 2025-03-28 22:00 |
Share Issue/Capital Change
Biophytis annonce le règlement-livraison de son placement privé de 2,6 millions…
|
French | 340.2 KB | ||
| 2025-03-26 07:35 |
Share Issue/Capital Change
Biophytis announces the successful completion of a €2,6 million private placeme…
|
English | 381.7 KB | ||
| 2025-03-26 07:35 |
Share Issue/Capital Change
Biophytis annonce le succès d'un placement privé d'environ 2,6 millions d'euros
|
French | 381.0 KB | ||
| 2025-03-24 07:30 |
Regulatory News Service
Biophytis announces new non-clinical data further supporting its mission to pio…
|
English | 242.6 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
